Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services. The company expects to close the transaction in the second half of 2014, subject to customary closing conditions. Boston Scientific Corporation (NYSE:BSX) net profit margin is -1.70% and weekly performance is 0.55%. On last trading day company shares ended up $12.80. Analysts mean target price for the company is $14.13. Boston Scientific Corporation (NYSE:BSX) distance from 50-day simple moving average (SMA50) is -2.86%.
Cyberonics, Inc. (NASDAQ:CYBX) announced positive results from the PuLsE (Open Prospective Randomized Long-term Effectiveness) study conducted at 28 sites in Europe and Canada and published in the peer-reviewed journal Epilepsia. The goal of this comparative effectiveness study, designed to reflect clinical practice, was to evaluate whether VNS Therapy plus BMP (“best medical practice,” defined as individualized therapy judged optimal by investigators at each visit for each patient) is superior to BMP alone in improving health-related quality of life (HRQoL). Cyberonics, Inc. (NASDAQ:CYBX) shares advanced 0.55% in last trading session and ended the day on $60.05. Gross Margin is 90.50% and its return on assets is 18.00%. Cyberonics, Inc. (NASDAQ:CYBX) quarterly performance is -16.27%.
Equities research analysts at Bank of America initiated coverage on shares of Cardiovascular Systems Inc (NASDAQ:CSII) in a research note issued to investors on Monday, Stock Ratings Network reports. The firm set a “buy” rating and a $38.00 price target on the stock. Bank of America’s price objective would indicate a potential upside of 38.33% from the company’s current price. Cardiovascular Systems Inc (NASDAQ:CSII) shares moved up 1.28% in last trading session and was closed at $26.20, while trading in range of $25.30 – $26.32. Cardiovascular Systems Inc NASDAQ:CSII) year to date (YTD) performance is -23.59%.
CONMED Corporation (NASDAQ:CNMD)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued on Friday,AnalystRatingsNetwork.com reports. They currently have a $47.00 price objective on the stock. Zacks‘s target price suggests a potential upside of 1.42% from the company’s current price. CONMED Corporation (NASDAQ:CNMD) ended the last trading day at $49.61. Company weekly volatility is calculated as 2.92 % and price to cash ratio as 23.99. CONMED Corporation (NASDAQ:CNMD) showed a positive weekly performance of 3.16%.
BioLife Solutions, Inc. (NASDAQ:BLFS) announced financial results for the first quarter of 2014 and a business update. Revenues were $2.1 million in the first quarter of 2014, a decline of 4% from the first quarter of 2013 which included one-time license revenue of $0.6 million. Excluding the impact of the license revenue in 2013, revenue from product sales increased 33% in the first quarter of 2014 compared with the first quarter of 2013. BioLife Solutions Inc (NASDAQ:BLFS) net profit margin is -12.40% and weekly performance is 25.12%. On last trading day company shares ended up $2.49. BioLife Solutions Inc (NASDAQ:BLFS) distance from 50-day simple moving average (SMA50) is -33.26%.
Leave a Reply